Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Update on soft tissue sarcomas].

Binh Nguyen Bui1, Reza Tabrizi, Corinne Dagada

  • 1Institut Bergonié, Centre régional de lutte contre le cancer, 229, cours de l'Argonne, 33076 Bordeaux Cedex.

Bulletin Du Cancer
|February 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue Sarcomas.

Cancers·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.

Cancer communications (London, England)·2025
Same author

Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2025
Same author

Prognostic prediction in soft-tissue sarcomas using deep learning and digital pathology of tumor and margin areas.

Scientific reports·2025
Same author

Multimodal prediction of metastatic relapse using federated deep learning in soft-tissue sarcoma with a complex genomic profile.

Scientific reports·2025

Recent advancements in soft tissue sarcoma diagnosis and treatment offer new hope. Improved diagnostics and targeted therapies like Glivec show promise for better patient outcomes in sarcoma care.

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Context:

  • Soft tissue sarcomas represent a heterogeneous group of rare malignancies.
  • Diagnostic criteria and classifications have evolved significantly.
  • Treatment strategies require continuous refinement based on new research.

Purpose:

  • To review recent advancements in the diagnosis and treatment of soft tissue sarcoma.
  • To highlight the impact of new diagnostic tools and therapeutic agents.
  • To discuss the potential of targeted therapies in sarcoma management.

Summary:

  • Diagnosis has been refined using immunohistochemistry, leading to the description of new entities and reclassification of others, such as the dismemberment of malignant histiocytoma.
  • Prognostic classification has improved with the UICC system, though the utility of novel biological and genetic markers requires further assessment.

Related Experiment Videos

  • Treatment breakthroughs include isolated limb perfusion with TNF, hyperthermia, and melphalan as alternatives to surgery or amputation, and systemic therapies like ecteinascidine (ET743) and Glivec (STI571).

    • Impact:

    • Enhanced diagnostic accuracy leading to more precise subtyping of soft tissue sarcomas.
    • Improved prognostic stratification enabling more tailored treatment planning.
    • Emergence of targeted therapies, exemplified by Glivec's efficacy in c-kit+ gastrointestinal stromal tumors, paving the way for precision oncology in sarcoma treatment.